Skip to main content
77°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.3590
+0.0118 (+3.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mainz Biomed N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
October 04, 2023
Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine
September 27, 2023
Pharma companies across the globe, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), are harnessing the potential of mRNA which is creating plenty of space for scientific improvement in...
Via
Benzinga
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
September 27, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
What 5 Analyst Ratings Have To Say About Mainz Biomed
September 26, 2023
Via
Benzinga
Where Mainz Biomed Stands With Analysts
June 01, 2023
Via
Benzinga
AI To Revolutionize Clinical Trials And Diagnostics
September 22, 2023
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
September 13, 2023
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of...
Via
Benzinga
Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention
September 13, 2023
By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology...
Via
Benzinga
Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
September 13, 2023
Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
September 13, 2023
It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday!
Via
InvestorPlace
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
September 13, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar
September 06, 2023
--News Direct--
Via
News Direct
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
September 05, 2023
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'...
Via
Benzinga
Exposures
COVID-19
10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar
September 05, 2023
The WHO reports that colorectal cancer is the second most fatal cancer around the world.
Via
Benzinga
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
September 05, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Second Most Fatal Cancer In U.S. May Face A Big Fight From Mainz Biomed’s Non-Invasive Test; (NASDAQ: MYNZ) Is Making Early Detection Possible
August 30, 2023
--News Direct--
Via
News Direct
Second Most Fatal Cancer In U.S. May Soon Face A Challenger: Mainz Biomed's (NASDAQ: MYNZ) Early Detection Tech
August 29, 2023
Colorectal cancer is the third most common cancer worldwide, and although the majority of colorectal cancer cases have historically occurred in individuals aged 45 and older, it is increasingly...
Via
Benzinga
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
August 29, 2023
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
August 22, 2023
Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland
From
Mainz BioMed NV
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
August 18, 2023
Via
Benzinga
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
August 15, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 14, 2023
Via
Benzinga
Why US Steel Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
August 14, 2023
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) shares surged 49.4% to $1.31 in pre-market trading after the company reported a 325% year-over-year growth in its second-quarter revenue.
Via
Benzinga
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
August 01, 2023
Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
July 18, 2023
Israel has one of the highest screening compliance rates in the world with over one million people being screened each year
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Secures up to $50M in New Funding
June 29, 2023
Provides option to access capital to support commercial and clinical programs
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
June 28, 2023
The Company’s innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
June 20, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Expands Commercial Footprint into Poland
May 31, 2023
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today
Via
PressReach
Topics
Death
Exposures
Death
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.